UNSPSC 51386006: Drinidene

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C10H9NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G715G2AW6N, chemically known as 1h-inden-1-one, 2-(aminomethylene)-2,3-dihydro- but generally known as drinidene, which bears US NIH Compound Identifier 3037167. European Medicines Agency schedules Drinidene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06400MIG.

UNSPSC 51386006 Drinidene is a Commodity code covering pharmaceutical products and related health supplies procured by state and local governments, though recent opportunities show the code applied to a narrower set of acquisitions: naloxone and drug deactivation systems, generic pharmaceuticals through cooperative purchasing, and pharmacy benefit program initiatives. State and local issuing bodies soliciting under this code span county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB with quarterly deliveries to a county health facility, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited manufacturers of generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities in Minnesota and Oregon. Vendors responding to these solicitations must meet federal compliance requirements including FDA registration, Drug Supply Chain Security Act (DSCSA) certification, current Good Manufacturing Practices (cGMP), and E-Verify employment eligibility confirmation, along with specified insurance coverages ranging from $2 million to $5 million in commercial general liability and professional liability limits.

Recent activity under the code centers on Florida and Minnesota, with broader multistate participation through MMCAP's cooperative purchasing vehicle. Seminole County's IFB for naloxone and drug deactivation systems closed July 26, 2023, with a two-year initial term and one-year renewal option on a fixed-fee basis. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, signaling emerging state interest in alternative pharmaceutical supply arrangements. MMCAP's RFP for generic pharmaceuticals and OTC products, posted January 20, 2026, with a March 26, 2026 response deadline, required vendor pricing submissions through authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) with contract awards effective July 1, 2026, emphasizing price competitiveness (75 percent of evaluation weight) and product availability, alongside compliance and administrative capability factors weighted at 25 percent combined.